United Therapeutics Corp (UTHR) — Analysis Summary
United Therapeutics Corp (UTHR) has a market cap of $22.64B with year-over-year revenue growth of +10.6%. Net margin stands at 41.9%. The stock trades at a P/E ratio of 17.3.
Key Takeaways
- Revenue changed +10.6% year-over-year
- Net margin of 41.9%
- P/E ratio of 17.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, UTHR posted revenue growth of +10.6% and trades at a P/E of 17.3.
United Therapeutics Corp (UTHR)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
1,400
Headquarters
SILVER SPRING, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.